lipegfilgrastim

DRUG4 trials

Sponsors

Merckle GmbH, Teva Branded Pharmaceutical Products R&D, Inc., Beaumont Hospital

Conditions

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced NeutropeniaBreast CancerEwing Family of Tumors, RhabdomyosarcomaPharmacodynamicsPharmacokinetics

Phase 1

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

CompletedNCT01585649

Merckle GmbHEwing Family of Tumors, Rhabdomyosarcoma

Start: 2012-07-31End: 2015-04-30Updated: 2016-05-18

PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

CompletedNCT02306915

Merckle GmbHPharmacodynamics, Pharmacokinetics

Start: 2014-10-31End: 2015-05-31Updated: 2021-11-09

Phase 3

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

CompletedNCT02044276

Teva Branded Pharmaceutical Products R&D, Inc.Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

Start: 2014-03-31End: 2018-04-24Updated: 2022-06-08

Unknown Phase

Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer

CompletedNCT02527317

Beaumont HospitalBreast Cancer

Start: 2015-01-31End: 2018-02-28Updated: 2018-02-09

Related Papers

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.

2020-09-177 citations